Who
Richard S. Lindahl
EVP, Chief Financial Officer
Company insider
Files Form 4 as: EVP, Chief Financial Officer, Emergent BioSolutions; Director, Compass Therapeutics; Chief Financial Officer, Ceb; Treasurer, Sprint Nextel.
In numbers
- Trades disclosed
- 179
- Buys
- 2
- Sells
- 2
- Bought
- $154K
- Sold
- $926K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 7 Feb 2006
- Last trade
- 8 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jun 2026filed 10 Jun 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $32K3,964 at $8.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $32K3,964 at $8.00 | filing |
| 29 Apr 2026filed 1 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —162,680 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —162,680 at $0.00 | filing |
| 5 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $200K23,650 at $8.44 | filing |
| 5 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $200K23,650 at $8.44 | filing |
| 3 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —72,856 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —72,856 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $5,566683 at $8.15 | filing |
| 1 Mar 2026filed 3 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $5,566683 at $8.15 | filing |
| 25 Feb 2026filed 6 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code H | —20,321 at $0.00 | filing |
| 25 Feb 2026filed 6 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code H | —20,321 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code D | $504K46,155 at $10.92 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $62K5,642 at $10.92 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code D | $504K46,155 at $10.92 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $62K5,642 at $10.92 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 15 Oct 2025filed 17 Oct 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $48K4,995 at $9.60 | filing |
| 8 Jun 2025filed 10 Jun 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $18K2,733 at $6.63 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Richard S. Lindahl; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.